Lee’s Pharm in-licensed China rights to distribute a second prescription drug product from Abiogen Pharma of Italy. In the latest deal, Lee’s will market Thorens® Cholecalciferol (vitamin D3) in mainland China, Hong Kong, Macau and Taiwan. Earlier this year, Lee’s gained China rights to Abioden’s Attila®, an orphan drug for brittle bone disease (see story). Vitamin D deficiency is a common cause of osteoporosis, especially in dialysis patients, whose kidneys often cannot process the vitamin.
Help employers find you! Check out all the jobs and post your resume.
